Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
PARP inhibitors are currently being used in clinical trials to treat BRCA1- or BRCA2-defective tumors, based on the synthetic lethal interaction between PARP1 and BRCA1/2-mediated homologous recombination (HR). However, the molecular mechanisms that drive this synthetic lethality remain unclear. Her...
| Autores principales: | , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
2012
|